JCA Repository

JCA Repository

Joint Clinical Assessment Reports

& Respective Summaries & Statements

Summary of the first four JCA Reports

Onasemnogene abeparvovec (September 7th, 2026)

JCA Report and affiliated Documents published by the European Commission

Clinical Guideline

Main clinical trial publication

Statement by the EAA

Tarlatamab (July 8th, 2026)

JCA Report and affiliated Documents published by the European Commission

Clinical Guideline

Main clinical trial publication

Joint Statement by Cancer Patients Europe (CPE) and EAA

Article by Lung Cancer Europe

Related Information:

Clinical Trial Evaluation by ESMO-MCBS Scorecard

Lurbinectedin (July 8th, 2026)

JCA Report and affiliated Documents published by the European Commission

Clinical Guideline

Main clinical trial publication

Joint Statement by Cancer Patients Europe (CPE) and EAA

Article by Lung Cancer Europe

Related Information:

Clinical Trial Evaluation by ESMO-MCBS Scorecard

Tovorafenib (June 9th, 2026)

JCA Report and affiliated Documents published by the European Commission

Clinical Guideline (EJC Recommendation)

Clinical Guideline (SIOPE Recommendation)

Main clinical trial publication

Joint Statement by Cancer Patients Europe (CPE) and EAA

Patient Organisations' Joint Statement

SIOPE Statement

EURORDIS Statement

The EAA is an initiative hosted by Copenhagen University, Utrecht University, Vlerick Business School, Agència de Qualitat I Avaluació Sanitàries de Catalunya, Erasmus University, LUISS Business School, Université Paris Cité, RIZIV/INAMI and endorsed & funded by:

Springer Healthcare, Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Roche, Sanofi , vfa, leem, EUCOPE and efpia.

The EAA Faculty is listed in the European Union Transparency Register and is a member of the HTA Stakeholder Network.

Share by: